Chromocell Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
0.660
+0.029 (4.60%)
At close: Nov 22, 2024, 4:00 PM
0.625
-0.035 (-5.29%)
After-hours: Nov 22, 2024, 5:54 PM EST
Company Description
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain.
The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family.
Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain.
Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Chromocell Therapeutics Corporation
| Country | United States |
| Founded | 2002 |
| IPO Date | Feb 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Francis Knuettel |
Contact Details
Address: 4400 Route 9 South, Suite 1000 Freehold, New Jersey 07728 United States | |
| Phone | 877 265 8266 |
| Website | chromocell.com |
Stock Details
| Ticker Symbol | CHRO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001919246 |
| ISIN Number | US1711261057 |
| Employer ID | 86-3335449 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Francis Knuettel II, M.B.A. | President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Director |
| Dr. Eric Lang M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 22, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 21, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 8-K12G3 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 424B3 | Prospectus |
| Nov 13, 2024 | 424B3 | Prospectus |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2024 | 8-K | Current Report |